Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1207 • 2019 ACR/ARP Annual Meeting
A Quality Improvement Intervention to Reduce 30-Day Hospital Readmission Rates Among Patients with Systemic Lupus Erythematosus
Emily Bowers¹, Melissa Griffith ¹, Elena Weinstein ¹, Duane Pearson ¹ and Jason Kolfenbach ¹, ¹University of Colorado Department of Rheumatology, Denver, CO
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic immune-mediated disease with significant morbidity and mortality that often requires inpatient hospitalization. SLE has one of the…
Abstract Number: 1590 • 2019 ACR/ARP Annual Meeting
Clinical and Sociodemographic Associates of Depression and Anxiety in Systemic Lupus Erythematosus
David Eldeiry¹, Moe Zandy ², Oshrat Tayer-Shifman ², Andrew Kwan ³, Sherief Marzouk ², Jiandong Su ², Kathleen Bingham ² and Zahi Touma ², ¹Royal College of Surgeons in Ireland, Dublin, Ireland, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Queens University, Kingston, ON, Canada
Background/Purpose: In our recent systematic review, we have shown a high prevalence for depression (35%) and anxiety (25.8%) in Systemic Lupus Erythematosus (SLE)1. A better…
Abstract Number: 1625 • 2019 ACR/ARP Annual Meeting
Severe Infection Prior to Diagnosis of Systemic Lupus Erythematosus (SLE) Is Associated with Disease-Specific Attributes and Long-Term Comorbidities
Yu Deng ¹, Anh Chung ², Abel Kho ¹, Yuan Luo ¹, Rosalind Ramsey-Goldman ² and Theresa Walunas², ¹Northwestern University, Chicago, ²Northwestern University, Chicago, IL
Background/Purpose: Lupus is a systemic autoimmune disease whose mechanism of development is largely unknown. Prior infection is a suspected sentinel event that may trigger disease…
Abstract Number: 1919 • 2019 ACR/ARP Annual Meeting
Development of a Multi-Modality Imaging Approach to Evaluate Lupus Nephritis
Amit Saxena ¹, David Karp ², Brad Rovin ³, Mikael Boesen ⁴, Olga Kubassova ⁵, Claire Dykas ⁶, Anthony Yeo ⁷ and Peter Lipsky⁸, ¹New York University School of Medicine, New York, NY, ²UTSouthwestern Medical Center, Dallas, TX, ³The Ohio State University Medical Center, Columbus, OH, ⁴Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁵Image Analysis Group, London, United Kingdom, ⁶AmpelBioSolutions, Charlottesville, VA, ⁷RILITE Research Institute, Charlottesville, VA, ⁸AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Lupus nephritis (LN) remains a significant cause of morbidity and mortality in subjects with Systemic Lupus Erythematosus (SLE). The gold standard for evaluation of…
Abstract Number: 2214 • 2019 ACR/ARP Annual Meeting
Assessment of Bone Quality by Trabecular Bone Score (TBS) in Systemic Lupus Erythematosus Patients
Andrea Casabella ¹, Sabrina Paolino ², Alberto Sulli³, Elisa Alessandri ⁴, Vanessa Smith ⁵, Barbara Ruaro ⁶, Carmen Pizzorni ² and Maurizio Cutolo ⁷, ¹1 Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genova, ⁵Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium; Dept. of Internal Medicine, Ghent University, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium, Gent, Belgium, ⁶1 Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 2 Cardinal Ferrari Centre, S. Stefano Rheabilitation, Fontanellato (Parma), Italy, Genoa, Italy, ⁷Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) patients show an increased risk of low bone mass as a result of multifactorial events: physical inactivity, persistent inflammation, low…
Abstract Number: 2531 • 2019 ACR/ARP Annual Meeting
Low Vitamin D Is Associated with Miscarriage and Preterm Birth in SLE with a U-shaped Relationship
Michelle Petri¹ and Jessica Li ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: In the general population, low vitamin D has been associated with adverse pregnancy outcomes including preterm birth, pre-eclampsia and small for gestational age. In…
Abstract Number: 2565 • 2019 ACR/ARP Annual Meeting
Pharmacokinetics and Exposure-response of Intravenous Belimumab in Children with Systemic Lupus Erythematosus
Richard Dimelow ¹, Beulah Ji² and Herbert Struemper ³, ¹GSK, Stevenage, United Kingdom, ²GSK, Uxbridge, Middlesex, United Kingdom, ³GSK, Research Triangle Park
Background/Purpose: Belimumab is approved in adults with active SLE and for childhood-onset SLE (cSLE). PLUTO, a Phase 2, placebo-controlled, double-blind trial (114055; NCT01649765), was the first…
Abstract Number: 2813 • 2019 ACR/ARP Annual Meeting
Pentameric, but Not Monomeric C-reactive Protein, Limits the SnRNP-immune Complex Triggered Type I Interferon Response: Implications for Lupus Pathogenesis
Cecilia Svanberg ¹, Helena Enocsson ¹, Klara Martinsson ¹, Lawrence Potempa ², Ibraheem Rajab ², Jonas Wetterö ¹, Marie Larsson ¹ and Christopher Sjöwall³, ¹Linköping University, Linköping, Sweden, ²Roosevelt University, Chicago, IL, ³Department of Clinical and Experimental Medicine, Rheumatology/Division of Neuro and Inflammation Sciences, Linköping University, Linköping, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune systemic disease affecting multiple organs and which is characterized by autoantibodies directed against nuclear constituents. Common autoantibody…
Abstract Number: 738 • 2018 ACR/ARHP Annual Meeting
Two Clinical Phenotypes of Chinese SLE-PAH Patients
Fangfang Sun¹, Wanlong Wu², Li Guo¹, Zhiwei Chen¹, Xiaodong Wang¹, Ting Li¹ and Shuang Ye¹, ¹Rheumatology, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, China, ²Department of Rheumatology, South Campus, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe complication of systemic lupus erythematosus (SLE), which is the most common underlying disease of CTD associated PAH.…
Abstract Number: 970 • 2018 ACR/ARHP Annual Meeting
Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Daniel J. Wallace¹, Richard Furie², Yoshiya Tanaka³, Kenneth C. Kalunian⁴, Marta Mosca⁵, Michelle Petri⁶, Thomas Dorner⁷, Mario H. Cardiel⁸, Ian N. Bruce⁹, Elisa Gomez¹⁰, Amy M. DeLozier¹⁰, Jonathan Janes¹⁰, Matthew D Linnik¹⁰, Stephanie de Bono¹⁰, Maria E. Silk¹⁰ and Robert W. Hoffman¹⁰, ¹Cedars-Sinai Medical Center/David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ²Division of Rheumatology, Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴University of California at San Diego School of Medicine, La Jolla, CA, ⁵University of Pisa, Pisa, Italy, ⁶Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Charité Universitätmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, ⁸Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, ⁹Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ¹⁰Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (Bari), an oral selective inhibitor of Janus kinase (JAK)1 and JAK2, has been approved for the treatment of RA in the Europe and…
Abstract Number: 1671 • 2018 ACR/ARHP Annual Meeting
Laboratory Investigation Results Influence Physician’s Global Assessment of Disease Activity in Systemic Lupus Erythematosus
Cynthia Aranow¹, Anca Askanase², Molla Huq³, Shereen Oon⁴, Alicia Calderone⁴, Eric Morand⁵ and Mandana Nikpour⁶, ¹Feinstein Institute for Medical Research, Mahasset, NY, ²Columbia University, College of Physicians & Surgeons, New York, NY, ³The University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁴The University of Melbourne at St. Vincent’s Hospital, Melbourne, Australia, ⁵Monash University, Melbourne, Australia, ⁶The University of Melbourne, Melbourne, Australia, Melbourne, Australia
Background/Purpose: The Physician Global Assessment (PGA) is a frequently-used outcome measure in Systemic Lupus Erythematosus (SLE). The PGA is intended to encapsulate the physician’s judgement…
Abstract Number: 1678 • 2018 ACR/ARHP Annual Meeting
How Consistently Do Publications Define SLE? a Systematic Review
Linjia Jia¹, Ecem Sevim², Medha Barbhaiya² and Michael Lockshin³, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Barbara Volcker Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is clinically heterogeneous. ACR and/or SLICC classification criteria provide homogeneous populations for research purposes, but studies differ in selection and…
Abstract Number: 1695 • 2018 ACR/ARHP Annual Meeting
Differences between Early and Adult-Onset Systemic Lupus Erythematosus in Cohort of Argentinian Patients
Rodrigo Aguila Maldonado¹, Dora Pereira², Gisela Pendon³, Alberto Spindler⁴, Cecilia N. Pisoni⁵, Julio Hofman⁶, María Victoria Collado⁷, Judith Sarano⁸, Cesar Graf⁹, Graciela N Gómez¹⁰, Paula Alba¹¹, Claudia Elizabeth Pena¹, Ana Carolina Costi¹², Adrian Salas¹³, Ana Curti¹⁴, Oscar Rillo¹⁵, Silvia Beatriz Papasidero¹⁶, Veronica Bellomio¹⁷, Susana Roverano¹⁸, Marcela Schmid¹⁹, Alberto Allievi²⁰, Sebastián Muñoz²⁰, Walter J. Spindler²¹, Andrea Gonzalez²², Ana María Beron²³, Rosana Quintana²⁴, Agustina Damico²⁵, Andrea Gómez²⁶, Sergio Tolosa²⁷, Enrique Soriano²⁸, Alicia Eimon²⁹, Marta Silvia Espósito⁶, Leila Romina Ferreyra Mufarregue³⁰, Juan Pablo Ruffino³⁰, Verónica Saurit³¹, Edson Hernán Chiganer³⁰, Fabian Risueño³², Flavia Caputo³³, Edson Velozo³⁴, Juan Soldano³⁵, Monica Diaz³⁶ and Mercedes Garcia¹, ¹Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, ²Rheumatology Section, Hospital Dr. Ricardo Gutiérrez, Argentina, Buenos Aires, Argentina, ³H Gutiérrez de La Plata, La Plata, Argentina, ⁴Centro Médico Privado de Reumatología, Centro Médico Privado de Reumatología, Argentina, ⁵Internal Medicine, CEMIC, Rheumatology and Immunology, CEMIC, Buenos Aires, Argentina, ⁶Consultorio Privado, Buenos Aires, Argentina, ⁷Rheumatology, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ⁸Instituto Lanari, Buenos Aires, Argentina, ⁹Centro Médico Mitre, Paraná, Argentina, ¹⁰Diaz Colodrero 2537 8° A, Instituto de Investigaciones Medicas Alfredo Lanari, Capital Federal, Argentina, ¹¹Universidad Nacional de Cordoba, Rheumatology Unit Cordoba and Materno Neonatal Hospital, Córdoba, Argentina, ¹²Rheumatology Section, HIGA General San Martin La Plata, La Plata, Argentina, ¹³Rheumatology, HIGA General San Martin, La Plata, Argentina, ¹⁴Htal Lagomaggiori, Mendoza, Argentina, ¹⁵Hospital General de Agudos Dr Ignacio Pirovano, Argentina, Buenos Aires, Argentina, ¹⁶Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, Argentina, Buenos Aires, Argentina, ¹⁷Hospital Padilla, San Miguel de Tucumán, Argentina, ¹⁸Hospital José Maria Cullen, Santa Fe, Argentina, ¹⁹Hospital Jose María Cullen, Santa Fe, Argentina, ²⁰SAR, Buenos Aires, Argentina, ²¹Centro Médico Privado de Reumatología, Tucuman, Argentina, ²²Hospital Eva Perón, San Martín, Argentina, ²³Hospital de Clínicas, Buenos Aires, Argentina, ²⁴Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Rosario, Argentina, ²⁵Hospital Británico, Buenos Aires, Argentina, ²⁶Hospital Británico de Buenos Aires, CABA, Argentina, ²⁷Hospital San Juan Bautista, San Fernando del Valle de Catamarca, Argentina, ²⁸Hospital Italiano, Buenos Aires, Argentina, ²⁹CEMIC, Buenos Aires, Argentina, ³⁰Hospital Durand, Buenos Aires, Argentina, ³¹Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ³²Itemédica, Bahia Blanca, Argentina, ³³Hospital Posadas, Buenos Aires, Argentina, ³⁴Sanatorio Adventista del Plata, Entre Ríos, Ecuador, ³⁵Hospital Provincial, Rosario, Argentina, ³⁶SAR, Bariloche, Argentina
Background/Purpose: Approximately 20% of patients with Systemic Lupus Erythematosus (SLE) begin their illness in childhood or adolescence. These patients are described with a phenotype of…
Abstract Number: 2668 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine and the Risk of Thrombotic Events in Systemic Lupus Erythematosus Patients : A Systematic Review and Meta-Analysis
Pratyaksha Sankhyan¹, Boonphiphop Boonpheng² and Christopher Cook², ¹Internal Medicine, East Tennessee State University, Johnson city, TN, ²Internal Medicine, East Tennessee State University, johnson city, TN
Hydroxychloroquine and Risk of Thrombosis in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysisAuthors : Sankhyan P, Boonpheng B, Cook CT Background/Purpose: Over…
Abstract Number: 2677 • 2018 ACR/ARHP Annual Meeting
A Systematic Review Examining the Association between Organ Damage and Health-Related Quality of Life in Systemic Lupus Erythematosus
Edward R. Hammond¹, Dora H. Lin², Irene B. Murimi², Henk Nab³, Hong Kan², Oluwadamilola Onasanya², Jonothan Tierce², Xia Wang¹, Barnabas Desta¹ and G. Caleb Alexander², ¹AstraZeneca, Gaithersburg, MD, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³AstraZeneca, Cambridge, United Kingdom
Background/Purpose: SLE-related organ damage is associated with increased morbidity. The comorbidity burden of SLE can involve various organ systems and may include pain, fatigue, difficulty…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].